Eli Lilly to share latest portfolio and pipeline findings in cancer research at ESMO Congress 2025

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting, taking place October 17-21 in Berlin, Germany. These presentations highlight the breadth of Lilly’s portfolio across treatment modalities and tumor types.

Presentation Highlights

 Verzenio (abemaciclib; CDK4/6 inhibitor):
 In a late-breaking oral presentation, Lilly will share results from the landmark seven-year analysis of monarchE, including primary overall survival analysis and updated invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. Additionally, in a mini-oral presentation, Lilly will share an in-depth analysis from monarchE examining the prognostic and predictive value of the Ki-67 index, pre- and post-neoadjuvant chemotherapy.

 Olomorasib (investigational KRAS G12C     inhibitor):
In a mini oral presentation, Lilly will share results from the Phase 1/2 study on the intracranial efficacy of olomorasib, a next-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) who have active, untreated brain metastases.

 LY4064809 (investigational pan-mutant-selective PI3Ka inhibitor):
 In a late-breaking oral presentation, Lilly will share updated results from the Phase 1/2 PIKALO-1 trial, a study of LY4064809 (STX-478), a pan-mutant-selective PI3Ka inhibitor, in PIK3CA-mutant advanced breast cancer and other solid tumors.

 Vepugratinib (investigational FGFR3 inhibitor):
 In a mini oral presentation, Lilly will share updated results from the FORAGER-1 study, a first-in-human Phase 1 study of vepugratinib (LY3866288), a potent, highly isoform-selective FGFR3 inhibitor, in FGFR3-altered urothelial cancer.

 LY4170156 (investigational ADC targeting FRα):
 In a poster presentation, Lilly will share updated safety and efficacy results from the Phase 1a/1b study of LY4170156 in patients with platinum-resistant ovarian cancer.

“At ESMO 2025, we’re proud to showcase new clinical data from several studies that underscore Lilly’s commitment to advancing cancer care, including the primary overall survival analysis for Verzenio in the Phase 3 monarchE trial, as well as updated safety and efficacy data from our FRα ADC, PI3Kα and FGFR3 programs, all of which are poised to advance to late stage studies over the next several months,” said Jacob Van Naarden, executive vice president and president of Lilly Oncology. “These data reflect the meaningful progress we have made in strengthening our oncology portfolio and our dedication to improving outcomes for people living with cancer.”

View a full list of abstract titles and viewing details HERE.